SE502344C2 - Hybridomcellinje med förmåga att producera monoklonala antikroppar jämte sätt att framställa cellinjen - Google Patents
Hybridomcellinje med förmåga att producera monoklonala antikroppar jämte sätt att framställa cellinjenInfo
- Publication number
- SE502344C2 SE502344C2 SE8300290A SE8300290A SE502344C2 SE 502344 C2 SE502344 C2 SE 502344C2 SE 8300290 A SE8300290 A SE 8300290A SE 8300290 A SE8300290 A SE 8300290A SE 502344 C2 SE502344 C2 SE 502344C2
- Authority
- SE
- Sweden
- Prior art keywords
- antibody
- hybridoma cell
- cell line
- human
- producing
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 106
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 210000004698 lymphocyte Anatomy 0.000 claims description 27
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 25
- 239000002609 medium Substances 0.000 claims description 25
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 25
- 238000000338 in vitro Methods 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 230000016784 immunoglobulin production Effects 0.000 claims description 9
- 238000001727 in vivo Methods 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000002349 favourable effect Effects 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 210000003917 human chromosome Anatomy 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 241000699729 Muridae Species 0.000 claims 4
- 210000000628 antibody-producing cell Anatomy 0.000 claims 2
- 238000011577 humanized mouse model Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 15
- 230000004927 fusion Effects 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 206010022000 influenza Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 4
- 229960005508 8-azaguanine Drugs 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- 239000000729 antidote Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- RIIWUGSYXOBDMC-UHFFFAOYSA-N benzene-1,2-diamine;hydron;dichloride Chemical compound Cl.Cl.NC1=CC=CC=C1N RIIWUGSYXOBDMC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000009177 immunoglobulin therapy Methods 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/166—Animal cells resulting from interspecies fusion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH409/82A CH652145A5 (de) | 1982-01-22 | 1982-01-22 | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
Publications (3)
Publication Number | Publication Date |
---|---|
SE8300290D0 SE8300290D0 (sv) | 1983-01-20 |
SE8300290L SE8300290L (sv) | 1983-07-23 |
SE502344C2 true SE502344C2 (sv) | 1995-10-09 |
Family
ID=4186382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE8300290A SE502344C2 (sv) | 1982-01-22 | 1983-01-20 | Hybridomcellinje med förmåga att producera monoklonala antikroppar jämte sätt att framställa cellinjen |
Country Status (17)
Country | Link |
---|---|
US (1) | US4634664A (de) |
JP (3) | JPS58128323A (de) |
AT (1) | AT388932B (de) |
CH (1) | CH652145A5 (de) |
CY (1) | CY1488A (de) |
DE (1) | DE3301249A1 (de) |
DK (1) | DK23183A (de) |
FI (1) | FI83538C (de) |
FR (1) | FR2522679B1 (de) |
GB (1) | GB2113715B (de) |
HK (1) | HK52589A (de) |
IL (1) | IL67721A (de) |
IT (1) | IT1160468B (de) |
KE (1) | KE3884A (de) |
MY (1) | MY8700169A (de) |
SE (1) | SE502344C2 (de) |
SG (1) | SG28189G (de) |
Families Citing this family (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1247538A (en) * | 1982-05-21 | 1988-12-28 | Mark C. Glassy | Human-human hybridomas for solid tumors |
US4613576A (en) * | 1983-03-09 | 1986-09-23 | Sloan-Kettering Institute For Cancer Research | Human monoclonal antibodies to cancer cells |
EP0148644A3 (de) * | 1984-01-06 | 1987-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Fusionspartner und seine Produkte |
US4634666A (en) * | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US4764465A (en) * | 1984-04-26 | 1988-08-16 | Cetus Corporation | Human monoclonal antibody against group A red blood cells |
JPS6187630A (ja) * | 1984-10-08 | 1986-05-06 | Teijin Ltd | 単純ヘルペスウイルスに対するヒトモノクロ−ナル抗体及びその製造法 |
DE3581400D1 (de) * | 1984-09-28 | 1991-02-21 | Teijin Ltd | Maus/mensch-hybridoma mit erzeugung von antiviralen menschlichen antikoerpern, deren herstellung und antivirale menschliche monoklonale antikoerper. |
US4693975A (en) * | 1984-11-20 | 1987-09-15 | The Wistar Institute | Human hybridroma fusion partner for production of human monoclonal antibodies |
JPS61155398A (ja) * | 1984-12-28 | 1986-07-15 | Teijin Ltd | 抗緑膿菌ヒトモノクロ−ナル抗体及びその製造法並びにそれを有効成分とする治療剤 |
USH1198H (en) | 1985-04-26 | 1993-06-01 | Cetus Corporation | Pseudomonas aeruginosa type-specific human monoclonal antibodies, their preparation and use |
US4677070A (en) * | 1985-04-26 | 1987-06-30 | Cetus Corporation | Pseudomonas aeruginosa exotoxin A antibodies, their preparation and use |
CH670098B (de) * | 1985-05-23 | 1989-05-12 | ||
JPH0720885B2 (ja) * | 1985-09-27 | 1995-03-08 | 帝人株式会社 | 単純ヘルペスウイルス感染症の予防又は治療剤 |
NZ218499A (en) * | 1985-12-10 | 1990-04-26 | Genetic Systems Corp | Monoclonal antibodies against pseudomonas aeruginosa, pharmaceutical compositions and detection methods |
AU613310B2 (en) * | 1986-04-01 | 1991-08-01 | Genelabs Incorporated | Immortalized virus-specific tissue cells |
WO1987005929A1 (en) * | 1986-04-01 | 1987-10-08 | Genelabs Incorporated | Immortalized cells which produce tissue-specific products |
US5565354A (en) * | 1986-09-05 | 1996-10-15 | Sandoz Ltd. | Production of human monoclonal antibodies specific for hepatitis B surface antigen |
US5646041A (en) * | 1987-02-12 | 1997-07-08 | Harfeldt; Elisabeth | Monoclonal antibody to herpes simplex virus and cell line producing same |
US5001065A (en) * | 1987-05-27 | 1991-03-19 | Cetus Corporation | Human cell line and triomas, antibodies, and transformants derived therefrom |
JPH01101896A (ja) * | 1987-10-14 | 1989-04-19 | Teijin Ltd | カンジダに対するヒト・モノクローナル抗体とその製造法 |
US5215913A (en) * | 1987-11-30 | 1993-06-01 | Roger Williams General Hospital | IgG-1 human monoclonal antibody reactive with an HIV-1 antigen and methods of use |
IT1226477B (it) * | 1988-07-04 | 1991-01-16 | Genetik Mab S R L | Linee cellulari n omas quale un mezzo per immortalare cellule produttrici di sostanze di qualunque specie animale. |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JP2535455B2 (ja) * | 1991-02-07 | 1996-09-18 | 帝人株式会社 | サイトメガロウイルスに対するヒト・モノクロ―ナル抗体を産生するハイブリド―マ |
EP0523949B1 (de) * | 1991-07-15 | 2003-06-25 | The Wellcome Foundation Limited | Herstellung von Antikörpern |
JPH05276984A (ja) * | 1991-09-05 | 1993-10-26 | Teijin Ltd | カンジダに対するヒト・モノクローナル抗体を産生するハイブリドーマ |
JPH05260961A (ja) * | 1992-05-21 | 1993-10-12 | Teijin Ltd | サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ |
BR9305557A (pt) * | 1992-06-26 | 1997-03-25 | Aetsrn | Anticorpos monoclonais humanos anti Rhesus-D e composiçao farmacêutica que os contém |
EP0583980A1 (de) * | 1992-08-20 | 1994-02-23 | Eli Lilly And Company | Verfahren zur Herstellung von monoklonalen Antikörpern aus Kaninchen |
HUT72546A (en) * | 1992-11-06 | 1996-05-28 | Sandoz Ag | Production of human monoclonal antibodies active against hepatitis b surface antigen |
US5750106A (en) * | 1993-01-28 | 1998-05-12 | Novartis Ag | Human monoclonal antibodies to cytomegalovirus |
US6046310A (en) * | 1996-03-13 | 2000-04-04 | Protein Design Labs., Inc. | FAS ligand fusion proteins and their uses |
JP4649602B2 (ja) | 1997-02-07 | 2011-03-16 | アメリカ合衆国 | 活性依存性向神経第▲iii▼因子(adnf▲iii▼) |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
EP1230269A2 (de) * | 1999-11-03 | 2002-08-14 | Maxygen, Inc. | Erzeugung von antikörperdiversität |
US7060802B1 (en) * | 2000-09-18 | 2006-06-13 | The Trustees Of Columbia University In The City Of New York | Tumor-associated marker |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
EP2796546B1 (de) | 2001-04-19 | 2017-08-09 | The Scripps Research Institute | Aufnahme von unnatürlichen Aminosäuren |
US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
US20030086929A1 (en) * | 2001-10-11 | 2003-05-08 | Tso J. Yun | Treatment of prostate cancer by inhibitors of ATP synthase |
EP2436774A3 (de) | 2002-08-01 | 2012-06-13 | The Regents of The University of California | Therapeutische monoklonale Antikörper zur Neutralisierung von Botulinumneurotoxinen |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
WO2008103472A2 (en) | 2007-02-23 | 2008-08-28 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US7321065B2 (en) * | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
ES2640669T3 (es) | 2003-05-19 | 2017-11-03 | Prothena Biosciences Limited | Fragmentos truncados de alfa-sinucleína en enfermedad con cuerpos de lewy |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
WO2005018539A2 (en) | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
EP2392923B1 (de) | 2003-06-18 | 2014-05-21 | The Scripps Research Institute | Methode zur Herstellung von Proteinen mit unnatürlichen Aminosäuren |
CA2879182C (en) | 2004-05-25 | 2017-02-14 | Medimmune, Inc. | Influenza hemagglutinin and neuraminidase variants |
US7973134B2 (en) * | 2004-07-07 | 2011-07-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
US7935790B2 (en) * | 2004-10-04 | 2011-05-03 | Cell Singaling Technology, Inc. | Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways |
US7807789B2 (en) * | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
EP2153848A3 (de) | 2005-01-27 | 2010-07-21 | The Regents of the University of California | Monoklonale therapeutische Antikörper zur Neutralisierung von Botulin-Neurotoxinen |
CN101107007B (zh) | 2005-01-27 | 2011-08-17 | 奥克兰儿童医院及研究中心 | 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗 |
EP1856271A4 (de) | 2005-03-08 | 2009-11-18 | Medimmune Vaccines Inc | Influenza-hämagglutinin- und neuraminidase-varianten |
US20090099340A1 (en) * | 2007-10-12 | 2009-04-16 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
EP1915620B1 (de) * | 2005-08-02 | 2010-06-02 | Xbiotech Inc | DIAGNOSE, BEHANDLUNG UND PRÄVENTION VON GEFÄSSERKRANKUNGEN MITTELS IL-1alpha-AUTOANTIKÖRPERN |
WO2007027906A2 (en) * | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
US20100151495A9 (en) * | 2005-08-31 | 2010-06-17 | Cell Signaling Technolgy, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
DOP2006000277A (es) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
JP5514539B2 (ja) | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物 |
WO2007119808A1 (ja) | 2006-04-13 | 2007-10-25 | Medical And Biological Laboratories Co., Ltd. | 融合パートナー細胞 |
US20090298093A1 (en) * | 2006-04-27 | 2009-12-03 | Roberto Polakiewicz | Reagents for the Detection of Protein Phosphorylation in ATM & ATR Kinase Signaling Pathways |
US20110008282A1 (en) * | 2006-05-15 | 2011-01-13 | Xbiotech, Inc. | IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
SI2109623T1 (sl) * | 2006-05-22 | 2012-05-31 | Xbiotech Inc | Zdravljenje raka z anti il protitelesi |
CA2657934C (en) | 2006-07-19 | 2017-04-04 | The Trustees Of The University Of Pennsylvania | Wsx-1/p28 as a target for anti-inflammatory responses |
US7939636B2 (en) * | 2006-08-11 | 2011-05-10 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in c-Src signaling pathways |
US20090258442A1 (en) * | 2006-08-31 | 2009-10-15 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US9598462B2 (en) | 2012-01-26 | 2017-03-21 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
WO2008083169A2 (en) * | 2006-12-26 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
US7989173B2 (en) * | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
CA2673659A1 (en) * | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Methods of detecting and diagnosing inflamatory responses and disorders by determining the level of soluble b7-h4 |
US20090142342A1 (en) * | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
PT3067066T (pt) | 2007-02-23 | 2019-06-17 | Univ California | Prevenção e tratamento da doença sinucleinopática e amiloidogénica |
EP1972639A3 (de) | 2007-03-07 | 2008-12-03 | Cell Signaling Technology, Inc. | Reagenzien zur Erkennung von Proteinphosphorylierung in Karzinom-Signalwegen |
US20090068684A1 (en) * | 2007-03-26 | 2009-03-12 | Cell Signaling Technology, Inc. | Serine and threoninephosphorylation sites |
US20080238709A1 (en) * | 2007-03-28 | 2008-10-02 | Faramarz Vaziri | One-way communication apparatus with dynamic key generation |
EP1983002A3 (de) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosinphosphorylations-Stellen und spezifische Antikörper |
US7977462B2 (en) | 2007-04-19 | 2011-07-12 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
EP1983003A3 (de) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosinphosphorylationsstellen und spezifische Antikörper |
US20090053831A1 (en) | 2007-05-01 | 2009-02-26 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
EP2185718B1 (de) | 2007-08-03 | 2017-10-04 | MUSC Foundation For Research Development | Menschliche monoklonale antikörper und verfahren zu ihrer herstellung |
CA2696263C (en) | 2007-08-15 | 2017-06-13 | Bing Liu | Monospecific and multispecific antibodies and method of use |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
WO2009029686A1 (en) | 2007-08-27 | 2009-03-05 | Longhorn Vaccines & Diagnostics Llc | Immunogenic compositions and methods |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
CA2861667C (en) | 2007-10-01 | 2017-06-13 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system and methods of use |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
JP2010540953A (ja) | 2007-10-05 | 2010-12-24 | ナショナル インスティテュート フォー バイオプロセッシング リサーチ アンド トレーニング リミテッド | 膵炎、敗血症および膵臓癌のためのグリコシル化マーカー |
EP2062920A3 (de) | 2007-11-21 | 2009-06-17 | Peter Hornbeck | Proteinphosphorylation durch basophilische Serin-/Threonin-Kinasen in Insulinsignalisierungspfaden |
US20090169549A1 (en) * | 2007-12-19 | 2009-07-02 | The Board Of Regents Of The University Of Texas System | Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use |
US20090220991A1 (en) * | 2008-02-29 | 2009-09-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
WO2009126306A2 (en) | 2008-04-10 | 2009-10-15 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
RU2498998C2 (ru) | 2008-05-30 | 2013-11-20 | ИксБиотеч, Инк. | АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ |
EP2309264A4 (de) * | 2008-06-06 | 2011-11-23 | Univ Toyama Nat Univ Corp | Grippevirusnachweisvorrichtung |
RU2523587C2 (ru) | 2008-07-11 | 2014-07-20 | МЕДИММЬЮН, ЭлЭлСи | Варианты гемагглютинина и нейрамидазы вируса гриппа |
JP5976319B2 (ja) * | 2008-09-12 | 2016-08-23 | エックスバイオテク,インコーポレイテッドXbiotech,Inc. | 病原性単球の標的化 |
US20100260752A1 (en) | 2009-01-23 | 2010-10-14 | Biosynexus Incorporated | Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria |
SG2014010185A (en) | 2009-02-12 | 2014-06-27 | Medimmune Llc | Influenza hemagglutinin and neuraminidase variants |
CA2761310C (en) | 2009-05-07 | 2017-02-28 | Charles S. Craik | Antibodies and methods of use thereof |
CN102666581A (zh) | 2009-08-31 | 2012-09-12 | 艾普利穆恩公司 | 用于抑制移植物排斥的方法和组合物 |
WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
KR102167261B1 (ko) | 2010-06-18 | 2020-10-20 | 엑스바이오테크, 인크. | 관절염 치료 |
EP2608808B1 (de) | 2010-08-23 | 2017-01-18 | XBiotech, Inc | Behandlung von neoplasieerkrankungen |
WO2012078688A2 (en) | 2010-12-06 | 2012-06-14 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
ES2697056T3 (es) | 2011-04-01 | 2019-01-21 | Xbiotech Inc | Tratamiento para patologías dermatológicas |
PT2750709T (pt) | 2011-09-23 | 2018-11-22 | Xbiotech Inc | Tratamento da caquexia |
US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
UA105278C2 (ru) | 2012-09-06 | 2014-04-25 | Інститут Біології Клітини Нан України | Способ получения каталитически активных антител (абзимов) с сиалидазной активностью |
US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
EP2904010A4 (de) | 2012-10-04 | 2016-06-01 | Xbiotech Inc | Behandlung von gefässerkrankungen und der damit verbundenen komplikationen |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
PE20152004A1 (es) | 2013-03-13 | 2016-02-07 | Prothena Biosciences Ltd | Inmunoterapia tau |
JP6450381B2 (ja) | 2013-07-05 | 2019-01-09 | ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション | がんを処置するための可溶性mic中和モノクローナル抗体 |
WO2015004632A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize iapp |
WO2015004633A1 (en) | 2013-07-12 | 2015-01-15 | Neotope Biosciences Limited | Antibodies that recognize islet-amyloid polypeptide (iapp) |
JP6463361B2 (ja) | 2013-09-08 | 2019-01-30 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | 第viii因子両性イオンポリマーコンジュゲート |
PT3116911T (pt) | 2014-03-12 | 2019-09-04 | Prothena Biosciences Ltd | Anticorpos anti-mcam e métodos de utilização associados |
KR20160131082A (ko) | 2014-03-12 | 2016-11-15 | 프로테나 바이오사이언시즈 리미티드 | Lg1-3에 특이적인 항-라미닌4 항체 |
CA2938933A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
TW201623331A (zh) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法 |
EP3129051A1 (de) | 2014-04-08 | 2017-02-15 | Prothena Biosciences Limited | Blut-hirn-schranken-shuttle mit antikörpern zur erkennung von alpha-synuklein |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
JP6849590B2 (ja) | 2014-10-17 | 2021-03-24 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート |
TWI718121B (zh) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
TWI769570B (zh) | 2015-01-28 | 2022-07-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
TWI718122B (zh) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
AU2016255768B2 (en) | 2015-04-29 | 2022-03-10 | Regeneron Pharmaceuticals, Inc. | Treatment of fibrodysplasia ossificans progressiva |
US9976136B2 (en) | 2015-05-14 | 2018-05-22 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
WO2017046776A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
KR20180104635A (ko) | 2015-12-30 | 2018-09-21 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
CU24537B1 (es) | 2016-05-02 | 2021-07-02 | Prothena Biosciences Ltd | Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6 |
PE20190208A1 (es) | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
WO2018007922A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
EP3478716A2 (de) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin-antikörper |
JP7016470B2 (ja) | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
KR20190025689A (ko) | 2016-07-06 | 2019-03-11 | 프로테나 바이오사이언시즈 리미티드 | 전체 및 s129 인산화된 알파-시누클레인을 검출하기 위한 검정 |
EP3582813A4 (de) | 2017-02-16 | 2020-12-30 | XBiotech, Inc | Behandlung von hidradenitis suppurativa |
AU2018250695A1 (en) | 2017-04-14 | 2019-11-07 | Kodiak Sciences Inc. | Complement factor D antagonist antibodies and conjugates thereof |
AU2018263935A1 (en) | 2017-05-02 | 2019-12-19 | Prothena Biosciences Limited | Antibodies recognizing tau |
BR112020001255A2 (pt) | 2017-07-21 | 2020-07-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | composições imunogênicas de neisseria meningitidis |
KR20200074201A (ko) | 2017-11-02 | 2020-06-24 | 바이엘 악티엔게젤샤프트 | Alk-1 및 bmpr-2에 결합하는 이중특이적 항체 |
KR20210094609A (ko) | 2018-11-28 | 2021-07-29 | 포티 세븐, 인코포레이티드 | 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc |
TW202045206A (zh) | 2019-02-27 | 2020-12-16 | 美商健生生物科技公司 | 抗體調配物 |
JP2022524588A (ja) | 2019-03-03 | 2022-05-09 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
BR112022013589A2 (pt) | 2020-01-08 | 2022-09-13 | Regeneron Pharma | Tratamento da fibrodisplasia ossificante progressiva |
WO2021211924A1 (en) | 2020-04-16 | 2021-10-21 | Janssen Biotech, Inc. | Treatment of atopic dermatitis |
WO2021247591A1 (en) | 2020-06-02 | 2021-12-09 | Arcus Biosciences, Inc. | Antibodies to tigit |
AU2022210371A1 (en) | 2021-01-22 | 2023-07-20 | Bayer Aktiengesellschaft | Lrrc15 antibodies and conjugates thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2757169A1 (de) * | 1977-12-22 | 1979-07-05 | Hoechst Ag | Verfahren zur gewinnung insulin produzierender tierischer zellen |
ZA806506B (en) * | 1979-11-01 | 1981-09-30 | Bio Response Inc | A method for production of monoclonal antibodies |
GB2079313A (en) * | 1980-07-07 | 1982-01-20 | Nat Res Dev | Improvements in or relating to rat myeloma cell lines |
DE3167442D1 (en) * | 1980-07-07 | 1985-01-10 | Nat Res Dev | Improvements in or relating to cell lines |
JPS57502090A (de) * | 1980-07-18 | 1982-11-25 | ||
JPS586475B2 (ja) * | 1980-08-23 | 1983-02-04 | 株式会社 林原生物化学研究所 | ヒト絨毛性性腺刺激ホルモンの製造方法 |
JPS6045849B2 (ja) * | 1980-08-25 | 1985-10-12 | 林原 健 | ヒトエリトロポエチンの製造方法 |
JPS585671B2 (ja) * | 1980-08-27 | 1983-02-01 | 株式会社 林原生物化学研究所 | ヒト卵胞刺激ホルモンの製造方法 |
JPS5743696A (en) * | 1980-08-27 | 1982-03-11 | Hayashibara Biochem Lab Inc | Preparation of human luteinizing hormone |
US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4529694A (en) * | 1982-04-16 | 1985-07-16 | The Children's Medical Center Corporation | Cell fusion |
-
1982
- 1982-01-22 CH CH409/82A patent/CH652145A5/de not_active IP Right Cessation
-
1983
- 1983-01-15 DE DE19833301249 patent/DE3301249A1/de active Granted
- 1983-01-19 GB GB08301384A patent/GB2113715B/en not_active Expired
- 1983-01-20 FR FR8300850A patent/FR2522679B1/fr not_active Expired
- 1983-01-20 FI FI830190A patent/FI83538C/fi not_active IP Right Cessation
- 1983-01-20 DK DK23183A patent/DK23183A/da not_active Application Discontinuation
- 1983-01-20 US US06/459,731 patent/US4634664A/en not_active Expired - Lifetime
- 1983-01-20 SE SE8300290A patent/SE502344C2/sv not_active IP Right Cessation
- 1983-01-20 IL IL67721A patent/IL67721A/xx unknown
- 1983-01-21 IT IT19234/83A patent/IT1160468B/it active
- 1983-01-21 AT AT0019583A patent/AT388932B/de not_active IP Right Cessation
- 1983-01-21 JP JP58009241A patent/JPS58128323A/ja active Granted
-
1987
- 1987-12-30 MY MY169/87A patent/MY8700169A/xx unknown
-
1989
- 1989-04-27 SG SG281/89A patent/SG28189G/en unknown
- 1989-05-16 KE KE3884A patent/KE3884A/xx unknown
- 1989-06-29 HK HK525/89A patent/HK52589A/xx not_active IP Right Cessation
- 1989-12-08 CY CY1488A patent/CY1488A/xx unknown
-
1990
- 1990-10-03 JP JP2267500A patent/JPH03236794A/ja active Granted
-
1991
- 1991-05-30 JP JP3157731A patent/JPH0789909B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
IT8319234A0 (it) | 1983-01-21 |
KE3884A (en) | 1989-08-11 |
FI830190L (fi) | 1983-07-23 |
JPH0365148B2 (de) | 1991-10-09 |
AT388932B (de) | 1989-09-25 |
GB2113715A (en) | 1983-08-10 |
ATA19583A (de) | 1989-02-15 |
CH652145A5 (de) | 1985-10-31 |
IT1160468B (it) | 1987-03-11 |
IL67721A (en) | 1986-04-29 |
MY8700169A (en) | 1987-12-31 |
DE3301249C2 (de) | 1990-04-05 |
SE8300290L (sv) | 1983-07-23 |
DE3301249A1 (de) | 1983-09-22 |
IL67721A0 (en) | 1983-05-15 |
SE8300290D0 (sv) | 1983-01-20 |
US4634664A (en) | 1987-01-06 |
FI830190A0 (fi) | 1983-01-20 |
FR2522679B1 (fr) | 1986-05-09 |
DK23183D0 (da) | 1983-01-20 |
FI83538B (fi) | 1991-04-15 |
HK52589A (en) | 1989-07-07 |
CY1488A (en) | 1989-12-08 |
JPH0789909B2 (ja) | 1995-10-04 |
GB8301384D0 (en) | 1983-02-23 |
FR2522679A1 (fr) | 1983-09-09 |
DK23183A (da) | 1983-07-23 |
JPH0690753A (ja) | 1994-04-05 |
FI83538C (fi) | 1991-07-25 |
JPH0471520B2 (de) | 1992-11-13 |
SG28189G (en) | 1989-08-11 |
JPS58128323A (ja) | 1983-07-30 |
GB2113715B (en) | 1986-06-04 |
JPH03236794A (ja) | 1991-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE502344C2 (sv) | Hybridomcellinje med förmåga att producera monoklonala antikroppar jämte sätt att framställa cellinjen | |
EP0014519B1 (de) | Zell-Linien, Verfahren zu ihrer Herstellung und Verfahren zur Herstellung von Antikörpern | |
CA1193562A (en) | Human hybridomas, precursors and products | |
US4594325A (en) | High fusion frequency fusible lymphoblastoid cell line | |
EP0488470A1 (de) | Verfahren zur Herstellung von Antikörpern | |
US4752582A (en) | Monoclonal antibodies to human glycophorin A and cell lines for the production thereof | |
EP2009094A1 (de) | Fusionspartnerzellen | |
EP0157574B1 (de) | Antitetanus-Antikörper herstellender Human-Human-Hybridoma und Verfahren zu seiner Herstellung | |
Garzelli et al. | Human monoclonal antibody to purified protein derivative of tuberculin produced by hybrids constructed with Epstein‐Barr virus‐transformed B lymphocytes and mouse myeloma cells | |
US4668629A (en) | Human hybridomas, precursors and products | |
Van Meel et al. | Human and chimpanzee monoclonal antibodies | |
JP3043023B2 (ja) | ハイブリドーマ | |
KR900007950B1 (ko) | 모노클로날 항체의 제조방법 | |
JPH0551277B2 (de) | ||
Chanu et al. | Heterohybridoma for the production of non murine monoclonal antibodies | |
Hirashima et al. | Preparation and characteristics of monoclonal antibodies reactive to satsuma dwarf virus | |
JPH02429A (ja) | ヒトbリンパ芽球様細胞株、抗体産生ハイブリドーマ、抗体および抗体の製造法 | |
Gore et al. | Incorporation of T cell counterparts in the fusion partners for generation of human monoclonal antibodies from Staphylococcus aureus stimulated B lymphocytes | |
GB2145113A (en) | Production of human monoclonal antibodies | |
CH670099A5 (en) | New hybridoma cell lines - obtd. by fusing mouse-human hybrid cells with human cells | |
JPH0679553B2 (ja) | 新規な雑種細胞 | |
JPS62104574A (ja) | 新規ハイブリド−マ | |
JPH06189750A (ja) | ヒト単クローン性抗肺ガン細胞抗体を産生するハイブリドーマ | |
JPH03271235A (ja) | 抗カンジダ菌抗体分泌ハイブリドーマ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NUG | Patent has lapsed |
Ref document number: 8300290-7 Format of ref document f/p: F |